Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use
- 8 March 2011
- journal article
- case report
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 170 (8) , 1075-1078
Abstract
Premature infants with preterm premature rupture of membranes (PPROM) are at high risk of severe respiratory failure because of lung hypodysplasia associated with persistent pulmonary hypertension of the newborn (PPHN). We describe the clinical course of a 28-week gestation infant with PPROM from the 20th week and prolonged oligohydramnios before delivery, who developed refractory hypoxia treated with oral bosentan as adjunct therapy to inhaled nitric oxide (iNO) and oral sildenafil. Conclusion Our experience suggests that bosentan can be used in the premature infant with PPHN after PPROM. To the best of our knowledge, this is the first report of bosentan treatment in a premature infant.Keywords
This publication has 23 references indexed in Scilit:
- Contemporary neonatal outcome following rupture of membranes prior to 25 weeks with prolonged oligohydramniosEarly Human Development, 2009
- [Sildenafil and nitric oxide inhalation in neonatal pulmonary hypertension. Three case reports].2008
- Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentanEuropean Journal of Pediatrics, 2007
- Physiopathologie des conséquences respiratoires néonatales de la rupture prématurée des membranes : application à la prise en charge néonataleArchives de Pédiatrie, 2007
- Combination pharmacotherapy for severe neonatal pulmonary hypertensionJournal of Paediatrics and Child Health, 2006
- Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertensionBritish Journal of Ophthalmology, 2004
- Nitric oxide treatment and acute pulmonary inflammatory response in very premature infants with intractable respiratory failure shortly after birthActa Paediatrica, 2003
- Interaction of endogenous endothelin-1 and inhaled nitric oxide in term and preterm infantsClinical Science, 2002
- Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failureThe Lancet, 1995
- Inhaled nitric oxide for premature infants after prolonged rupture of the membranesThe Journal of Pediatrics, 1995